TABLE 2.

Efficacy and Dose of IDegLira and iGlarLixi in Phase 3 Trials

PopulationPatients With Type 2 Diabetes Uncontrolled on Basal InsulinPatients With Type 2 Diabetes Uncontrolled on a GLP-1 Receptor Agonist
TrialDUAL II (47)DUAL V (48)LixiLan-L (50)DUAL III (49)
TreatmentIDegLiraInsulin degludecIDegLiraInsulin glargine U100iGlarLixiInsulin glargine U100IDegLiraUnchanged GLP-1 receptor agonist
n199199278279367369292146
A1C (%)
 Baseline8.7 (0.7)8.8 (0.7)8.4 (0.9)8.2 (0.9)8.1 (0.7)8.1 (0.7)7.8 (0.6)7.7 (0.5)
 End of trial6.9 (NR)8.0 (NR)6.6 (0.9)7.1 (0.9)6.9 (0.9)7.5 (0.9)6.4 (0.8)7.4 (1.0)
 Change–1.9* (NR)–0.9 (NR)–1.81 (1.08)–1.13 (0.98)–1.1 (SE 0.06)*–0.6 (SE 0.06)–1.3 (0.9)*–0.3 (0.9)
Responders (%)
 A1C <7%60.3*23.171.6*47.055*3075*36
 A1C ≤6.5%45.2*13.155.4*30.834*1463*23
FPG (mg/dL)
 Baseline175 (52)173 (56)160.6 (47.5)159.8 (52.0)131.5 (36.0)133.3 (37.8)161.7 (38.2)169.1 (41.7)
 End of trial112 (NR)126 (NR)109.5 (38.4)110.2 (38.6)122.5 (41.4)120.7 (37.8)108.5 (29.3)158.4 (48.7)
 Change–62 (53)*–46 (60)–50.9 (NR)–49.9 (NR)–7.2 (SE 1.8)–9.0 (SE 1.8)–53.6 (41.1)*–10.7 (49.3)
End of trial dose (units)45454166474743NA
  • Data are mean (SD) unless otherwise stated.

  • * Significant difference between treatments in favor of IDegLira/iGlarLixi.

  • NA, not applicable;

  • NR, not reported;

  • SE, standard error.